Study on the situation of female sexual dysfunction in different reproductive aging stages and postmenopausal women using hormone replacement therapy

doi:10.3969/j.issn.1006-7795.2021.04.005

Journal of Capital Medical University ›› 2021, Vol. 42 ›› Issue (4): 533-539.doi: 10.3969/j.issn.1006-7795.2021.04.005

• Menopause, Gynecological Endocrinology and Fertility Preservation • Previous Articles Next Articles

Study on the situation of female sexual dysfunction in different reproductive aging stages and postmenopausal women using hormone replacement therapy

Ju Rui¹, Ruan Xiangyan^1*, Dai Yinmei¹, Bai Yongtao², Yang Xingzi², Shi Yanhong², Xu Xin¹, Yang Yu¹, Cheng Jiaojiao¹, Sun Yanhua³, Li Ruiling³

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department of Gynecology, Beijing Chaoyang District Taiyanggong Community Health Service Center, Beijing 100028, China;
3. Department of Gynecology, Beijing Chaoyang District Maternal and Child Health Care Hospital, Beijing 100022, China

Received:2021-05-18 Online:2021-08-21 Published:2021-07-29
Contact: * E-mail:ruanxiangyan@ccmu.edu.cn
Supported by:
Beijing Municipal Administration of Hospitals' Ascent Plan(DFL20181401),China Health Promotion Foundation (CHPF-2018-OP-11),National Menopause Health Care Specialist Construction Unit of China [(2020)30], The First Batch of Beijing Maternal and Child Health Specialist Demonstration Units “Menopausal Health Specialist”[(2017) 35].

Abstract

Abstract: Objective To investigate the situation of female sexual dysfunction (FSD) at different reproductive stages and the situation of FSD at postmenopausal women using hormone replacement therapy (HRT). Methods A multicenter clinical study was conducted among 902 women in the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University and other two medical alliance institutions from Jun. 2019 to Aug. 2020. According to the 2011 stages of the Reproductive Ageing Workshop (STRAW+10) and postmenopausal women using HRT or not, the subjects were divided into seven groups: 146 women in reproductive age (R), 199/87 women in early (ET)/late (LT) menopausal transition, 183/41 women in early (EP)/late (LP) postmenopause. Totally 207 women in early postmenopausal stage using estradiol sequentially combined with dydrogesterone (EP-HRT) and 39 women in late postmenopausal stage using estradiol combined with drospirenone administered continuously (LP-HRT). The Female Sexual Function Index (FSFI) was used to assess FSD. Results In group EP and LP, the proportion of FSD, sexual desire disorder, lubrication disorder, dissatisfaction and pain was significantly higher than those in R, ET and LT groups (P＜0.05). In group LP, the proportion of arousal disorder and orgasm disorder was significantly higher than those in R and ET groups (P＜0.05). The proportion of sexual desire disorder, orgasm disorder in LT group, the proportion of orgasm disorder in EP group, and the proportion of arousal disorder in LP group was significantly higher than those in R group. The proportion of lubrication disorder and pain in LP group was significantly higher than those in EP group (P＜0.05). Comparing EP group versus EP-HRT group, the proportion of FSD, sexual desire disorder and dissatisfaction was significantly lower in EP-HRT group (P＜0.05). Comparing LP group versus LP-HRT group, the proportion of FSD, lubrication disorder, dissatisfaction and pain was significantly lower in LP-HRT group (P＜0.05). Conclusion There was a clear association between deteriorating sexual function and increasing STRAW+10 classification, suggesting the consequence of decreasing ovarian function. HRT containing ‘natural hormones' imposed a beneficial effect on FSD.

Key words: female sexual dysfunction, Female Sexual Function Index(FSFI), Stages of Reproductive Aging Workshop(STRAW+10) criteria, hormone replacement therapy

CLC Number:

R711.75

Ju Rui, Ruan Xiangyan, Dai Yinmei, Bai Yongtao, Yang Xingzi, Shi Yanhong, Xu Xin, Yang Yu, Cheng Jiaojiao, Sun Yanhua, Li Ruiling. Study on the situation of female sexual dysfunction in different reproductive aging stages and postmenopausal women using hormone replacement therapy[J]. Journal of Capital Medical University, 2021, 42(4): 533-539.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/533

References

[1] Zhang C, Tong J, Zhu L, et al. A population-based epidemiologic study of female sexual dysfunction risk in mainland china: prevalence and predictors[J]. J Sex Med,2017,14(11):1348-1356.
[2] Heidari M, Ghodusi M, Rezaei P, et al. Sexual function and factors affecting menopause: a systematic review[J]. J Menopausal Med,2019,25(1):15.
[3] 鞠蕊,阮祥燕,许新,等. 围绝经期及绝经后女性性功能障碍状况及与更年期症状的关系分析[J]. 首都医科大学学报,2020,41(4):503-507.
[4] 金凤羽,阮祥燕,Mueck Alfred O.,等. 北京及周边地区围绝经期女性性功能现状调查分析[J]. 首都医科大学学报,2017,38(4):509-514.
[5] 阮祥燕,杨欣. 围绝经期异常子宫出血诊断和治疗专家共识[J]. 中华妇产科杂志,2018,53(6):396-401.
[6] Harlow S D, Gass M, Hall J E, et al. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging[J]. Climacteric,2012,15(2):105-114.
[7] Sun X, Li C, Jin L, et al. Development and validation of Chinese version of female sexual function index in a Chinese population-a pilot study[J]. J Sex Med,2011,8(4):1101-1111.
[8] Simon J A, Davis S R, Althof S E, et al. Sexual well-being after menopause: an international menopause society white paper[J]. Climacteric,2018,21(5):415-427.
[9] Baber R J, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy[J]. Climacteric,2016,19(2):109-150.
[10] 陈蓉,林守清. 构建中的生殖衰老分期——生殖衰老分期+10专题研讨会总结摘译[J]. 中国实用妇科与产科杂志,2012,28(9):713-715.
[11] Lou W J, Chen B, Zhu L, et al. Prevalence and factors associated with female sexual dysfunction in Beijing, China[J]. Chin Med J (Engl),2017,130(12):1389-1394.
[12] Tong J, Zhang C, Zhu L, et al. Sexual dysfunction in perimenopausal women based on a national epidemiological survey in China[J]. Climacteric,2019,22(2):190-194.
[13] Zhou Y, Li C, Jin F, et al. Prevalence and predictors of sexual function in midlife partnered Chinese women assessed by two simple indicators: Sexual frequency and sexual desire[J]. J Obstetr Gynaecol Res,2019,45(1):210-216.
[14] Worsley R, Bell R J, Gartoulla P, et al. Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women[J]. J Sex Med,2017,14(5):675-686.
[15] Dąbrowska-Galas M, Dąbrowska J, Michalski B. Sexual dysfunction in menopausal women[J]. Sex Med,2019,7(4):472-479.
[16] 赵婉君,罗晗,韩倩倩,等. 成都市女性性功能障碍的调查与相关因素的探析[J]. 中国性科学,2017,26(6):61-65.
[17] Da S L L, Useche B, Rosa E S J, et al. Sexuality during the climacteric period[J]. Maturitas,2009,62(2):127-133.
[18] Blumel J E, Castelo-Branco C, Binfa L, et al. Quality of life after the menopause: a population study[J]. Maturitas,2000,34(1):17-23.
[19] Thomas H N, Neal-Perry G S, Hess R. Female sexual function at midlife and beyond[J]. Obstetr Gynecol Clin North Am,2018,45(4):709-722.
[20] Wong E L Y, Huang F, Cheung A W L, et al. The impact of menopause on the sexual health of Chinese Cantonese women: A mixed methods study[J]. J Adv Nursing,2018,74(7):1672-1684.
[21] Bell R J, Rizvi F, Islam R M, et al. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy[J]. Menopause,2018,25(6):704-709.
[22] Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition[J]. Fertil Steril,2002,77(Suppl 4):S42-S48.
[23] Nijland E A, Weijmar S W, Nathorst-Boos J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial[J]. J Sex Med,2008,5(3):646-656.
[24] Cappelletti M, Wallen K. Increasing women's sexual desire: the comparative effectiveness of estrogens and androgens[J]. Horm Behav,2016,78:178-193.
[25] American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology Female sexual dysfunction. ACOG Practice Bulletin Clinical Management Guidelines for obstetrician-gynecologists, number 213[J]. Obstet Gynecol, 2019,134(1):e1-e18.

Study on the situation of female sexual dysfunction in different reproductive aging stages and postmenopausal women using hormone replacement therapy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Ju Rui, Ruan Xiangyan, Dai Yinmei, Bai Yongtao, Yang Yu, Xu Xin, Cheng Jiaojiao, Yang Xingzi, Shi Yanhong, Sun Yanhua, Li Ruiling. Influencing factors of female sexual dysfunction in Chinese women [J]. Journal of Capital Medical University, 2022, 43(3): 357-363.
[2]	Ju Rui, Ruan Xiangyan, Xu Xin, Yang Yu, Zhang Luping, Qin Shuang, Wang Binhong, Dou Zhuli, Alfred O. Mueck. Prevalence of female sexual dysfunction and the relationship between climacteric symptoms and female sexual dysfunction in Chinese women with menopause transition stage and postmenopausal stage [J]. Journal of Capital Medical University, 2020, 41(4): 503-507.
[3]	Du Juan, Ruan Xiangyan, Alfred O. Mueck. Effects of oral contraceptives on sexual function in PCOS patients [J]. Journal of Capital Medical University, 2018, 39(4): 499-504.
[4]	Fang Ying, Hong Liming, Yang Xiaokui. A gonadotrophin-releasing hormone agonist(GnRHa) suppression protocol versus normal hormone replacement therapy(HRT) protocol in multiple implantation failed patients undergoing frozen-embryo transfer cycles [J]. Journal of Capital Medical University, 2015, 36(4): 544-547.
[5]	YIN Dongmei, LIU Zhen, Ruan Xiangyan, WANG Juan. Impact of hormone therapy on quality of life of women with menopausal syndrome [J]. Journal of Capital Medical University, 2013, 34(3): 428-431.